# Organosilane for surface cleaning in intensive care units: protocol for a cluster randomized controlled trial with crossover

**Authors:** Antonio Paulo Nassar, Claudia Vallone Silva, Camila Gosenheimer Righi, Isabella Lott Bezerra, Andrea de Carvalho, Ana Cristina Lagoeiro Patrocínio, Eduvirgens Maria Couto de Souza, Mirian Batista Rodrigues, Tiago Mendonça dos Santos, Luiz Felipe Valter de Oliveira, Ana Paula Christoff, Bianca Luise Teixeira, Bruno Adler Maccagnan Pinheiro Besen, Viviane Cordeiro Veiga, Alexandre Biasi Cavalcanti, Bruno Martins Tomazini, Adriano José Pereira

PMC · DOI: 10.62675/2965-2774.20250319 · Critical Care Science · 2025-06-30

## TL;DR

This study will test if using organosilane for surface cleaning in intensive care units reduces healthcare-associated infections.

## Contribution

The study introduces a novel protocol for evaluating organosilane as a disinfectant in intensive care units through a cluster randomized controlled trial.

## Key findings

- The trial will measure the incidence of ventilator-associated pneumonia and other infections.
- It will assess the impact of organosilane on multidrug-resistant microorganism contamination.
- The cost of ICU stays will be analyzed as a secondary outcome.

## Abstract

To assess whether surface disinfection with organosilane in the intensive care unit reduces the occurrence of healthcare-associated infections.

This multicenter, controlled, cluster-randomized trial includes 14 intensive care units in Brazil from November 2023 to December 2024. The local hygiene team of the included intensive care units will disinfect bed surfaces with organosilane or with usual care for 6 months, followed by a sequential crossover of another 6 months. The primary outcome is the incidence of healthcare-associated infections, specifically ventilator-associated pneumonia, central-line-associated bloodstream infections, and catheter-associated urinary tract infections. The secondary endpoints are the contamination of the environment by multidrug-resistant microorganisms (i.e., oxacillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecium, carbapenem-resistant Enterobacter, Pseudomonas, and Acinetobacter), the incidence of specific infections (i.e., ventilator-associated pneumonia, central-line associated bloodstream infection, and catheter-associated urinary tract infection) and the cost of the patient's intensive care unit stay. We will enroll all adult patients admitted after the study begins in each participant's intensive care unit.

The institutional review board of the coordinator center and each enrolled center approved the study protocol. We will disseminate the results in peer-reviewed journals and at scientific meetings, regardless of the study's outcome.

## Linked entities

- **Chemicals:** oxacillin (PubChem CID 6196), vancomycin (PubChem CID 14969), carbapenem (PubChem CID 441133)
- **Species:** Staphylococcus aureus (taxon 1280), Enterococcus faecium (taxon 1352), Enterobacter (taxon 547), Pseudomonas (taxon 286), Acinetobacter (taxon 469)

## Full-text entities

- **Diseases:** infections (MESH:D007239), ventilator-associated pneumonia (MESH:D053717), urinary tract infection (MESH:D014552), bloodstream infection (MESH:D018805)
- **Chemicals:** carbapenem (MESH:D015780), oxacillin (MESH:D010068), Organosilane (MESH:D017646), vancomycin (MESH:D014640)
- **Species:** Pseudomonas (RNA similarity group I, genus) [taxon 286], Staphylococcus aureus (species) [taxon 1280], Acinetobacter (genus) [taxon 469], Enterococcus faecium (species) [taxon 1352], Homo sapiens (human, species) [taxon 9606], Enterobacter (genus) [taxon 547]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12266816/full.md

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC12266816/full.md

## References

25 references — full list in the complete paper: https://tomesphere.com/paper/PMC12266816/full.md

---
Source: https://tomesphere.com/paper/PMC12266816